Initial Results of a Prospective Study and Identification of New Strategies to Increase Traceability of Plasma-derived Medicines

Plasma medicine is an innovative and emerging field used in a broad range of medical conditions. the present study focused on consumption and documentation pattern of plasma- derived medicines in a teaching hospital. a two-step study was conducted from october to december 2015. during the first phase, the patient records receiving plasma-derived medicines including coagulation factor viii, ix, prothrombin complex concentrate, factor viii/von wilberand complex, anti-hepatitis b immunoglobulin, intravenous immunoglobulin, anti- tetanus immunoglobulin, and albumin were checked to assess recording details of these medications at the time of administration. adverse events reported with the mentioned products were examined from traceability viewpoint. the second step concentrated on practical strategies to improve documentation status of plasma-derived medicines in the hospital. we proposed national guideline as the first strategy and a new barcoding system to track and identify drug information of plasma medicines. of the expected drug information, only generic name, dosage from, and strength were recorded after administration. post-marketing safety surveillance of the plasma products was poor similarly. unavailability of suitable instructions was the main reason for documentation deficiency. a guideline was designed and implemented to inform healthcare professionals about essentials of appropriate documentation for plasma-derived medicines. updated results of the ongoing phase will be submitted soon. our survey highlights the importance of documentation as a key component of plasma-derived medicine ssurveillance within the hospitals.